From our point of view, Bioxtran is a highly undervalued asset with exceptionally strong clinical trial data that warrants further development. We are very happy to provide the capital needed to ...

The phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in ...

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...

An experimental blood test for pancreatic cancer is being evaluated by a commercial laboratory, an important milestone toward ...

Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and diabetes ...

EDETEK Inc., a digital clinical platform company, announced the launch of R&D Cloud, a software ecosystem that addresses ...

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...

Ms. Andor will lead the Company’s expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute ...

UofL was recently awarded its largest clinical research investment in the institution's history with $11.7 million from the ...